Page 16 - Compass Pathways News Today

Thinking outside the box has been a hallmark of Elon Musk’s behavior, and now you might be curious about how he actually reaches those ‘out of the box’ thought patterns. Musk has recently been touting the credentials of ketamine, an anesthetic known for its dissociative qualities. The Tesla CEO has said that he occasionally indulges in microdosing of the drug, believing it to be a better choice than traditional antidepressants for treating depression. Musk has also mentioned...

New York (PRWEB) June 22, 2023 -- The Healthcare Technology Report is pleased to announce The Top 25 Healthcare Technology Leaders of New York for 2023. This

Wall Street might have the timing wrong, but their hopes aren't misplaced.

The U.S. Food and Drug Administration on Friday issued its first draft guidance on psychedelic drug clinical trials, outlining considerations for companies...

New York (PRWEB) June 22, 2023 -- The Healthcare Technology Report is pleased to announce The Top 25 Healthcare Technology Leaders of New York for 2023. This

Psychedelic stocks are trading so low right now that there is no better time to invest, according to one venture capital firm. Investors have been given...

Psychedelics startups want to transform mental healthcare. But first, they need to win over the skeptics and break the taboos.

Numinus Wellness Inc. (TSX:NUMI, OTC:LKYSF) said its wholly-owned subsidiary Cedar Clinical Research (CCR) has begun studying COMP360 psilocybin therapy, an...

Shares of Compass Pathways PLC climbed on Friday after the U.S.-listed healthcare group announced a successful follow-up study of a psychedelic drug used to…

As the psychedelic medicine gold rush accelerates, there are ways to game the system and some companies are testing the limits of patent law.